Futura Medical has partnered with OCT Clinical to run its FM71 clinical study for MED3000 in erectile dysfunction in four countries: Bulgaria, Poland, Georgia, and the USA. The companies have already reported the first patient entering the screening in Georgia earlier this week.
This is a multi-center, randomized, open-label, home use, parallel group, clinical investigation of topically-applied MED3000 gel and oral tadalafil tablets for the treatment of erectile dysfunction (ED) over a 24-week period. This clinical investigation is intended to assess the efficacy and safety of MED3000 gel in 100 male patients clinically diagnosed with a mix of mild, moderate, and severe ED. The enrollment target will include 20 African American patients (from the US) and 80 patients from Eastern Europe, who will undergo a seven-month study.
Read the full article at Applied Clinical Trials official website.[1]
[1] https://www.appliedclinicaltrialsonline.com/view/futura-medical-partners-with-oct-clinical-to-run-fm71-study
